Sessile Serrated LesionNCT07678788
Study on the Association Between Serrated Polyps and Metachronous Advanced Colorectal Neoplastic Lesions
An observational study of Sessile Serrated Lesion and Serrated Polyp, run by Changhai Hospital.
Trial summary
This study aims to explore the risk factors associated with the development of ACN and same-site ACN in patients with SP, thereby informing the optimization of clinical surveillance strategies Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sessile Serrated Lesion, Serrated Polyp
- How many people
- 750 participants
- Where
- No sites listed yet
- Study dates
- 1 Jun 2026to 1 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients who underwent at least two surveillance colonoscopies at the Digestive Endoscopy Center of Shanghai Changhai Hospital between 2000 and 2025 were enrolled as study participants
Who may be able to join
- Adult patients aged > 18 years;At least one SP detected during the index colonoscopy and pathologically confirmed as TSA or SSL (according to the 2019 WHO classification criteria);Underwent complete polypectomy during the index colonoscopy;Received regular follow-up at Changhai Hospital, with an interval of ≥ 6 months between the index and follow-up colonoscopies;Complete clinical and pathological data.
Who cannot join
- Incomplete colonoscopy or failed cecal intubation;Inadequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) score < 6 or a score < 2 in any bowel segment;Withdrawal time < 6 minutes;Diagnosis of hereditary cancer syndromes, such as familial adenomatous polyposis (FAP) or Lynch syndrome;Concurrent inflammatory bowel disease (IBD) or indeterminate colitis;History of colorectal cancer or other malignancies;Incomplete clinical or pathological records.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Risk Factors for Metachronous Advanced Colorectal Lesions After Endoscopic Resection of Serrated Lesions
This study aims to explore the risk factors associated with the development of ACN and same-site ACN in patients with SP, thereby informing the optimization of clinical surveillance strategies
- Conditions
- Sessile Serrated Lesion, Serrated Polyp
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with serrated polyps at index colonoscopy and ACN at surveillance | Not described | |
| Patients with serrated polyps at index colonoscopy and no ACN at surveillance | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The occurrence of metachronous ACN
Measured: At least 6 months after index colonoscopy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2026
- Study start1 Jun 2026 (estimated)
- Primary completion30 Aug 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Sessile Serrated LesionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 750 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Changhai Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07678788
- Sponsor's protocol ID
- 34435353
- Status last verified
- May 2026
- First submitted
- 25 Jun 2026
- Last updated
- 1 Jul 2026
- Results posted
- No
- Individual data sharing
- No
Publications
[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J/OL]. CA: A Cancer Journal for Clinicians, 2020, 70(1): 7-30. DOI:10.3322/caac.21590. [2] NAGTEGAAL I D, ODZE R D, KLIMSTRA D, et al. The 2019 WHO classification of tumours of the digestive system[J/OL]. Histopathology, 2020, 76(2): 182-188. DOI:10.1111/his.13975. [3] LI D, LIU L, FEVRIER H B, et al. Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps[J/OL]. Gastroenterology, 2020, 159(2): 502-511.e2. DOI:10.1053/j.gastro.2020.04.004. [4] ERICHSEN R, BARON J A, HAMILTON-DUTOIT S J, et al. Increased Risk of Colorectal Cancer Development Among Patients With Serrated Polyps[J/OL]. Gastroenterology, 2016, 150(4): 895-902.e5. DOI:10.1053/j.gastro.2015.11.046. [5] BAILE-MAXÍA S, MANGAS-SANJUÁN C, LADABAUM U, et al. Risk factors for metachronous colorectal cancer or advanced lesions after endoscopic resection of serrated polyps: a systematic review and meta-analysis[J/OL]. Gastrointestinal Endoscopy, 2024, 100(4): 605-615.e14. DOI:10.1016/j.gie.2024.05.021. [6] TRIVEDI M, GODIL S, DEMB J, et al. Baseline Characteristics and Longitudinal Outcomes of Traditional Serrated Adenomas: A Cohort Study[J/OL]. Clinical Gastroenterology and Hepatology, 2023, 21(6): 1637-1645. DOI:10.1016/j.cgh.2022.09.030. [7] HE D, WANG K, ZHANG Y, et al. Risk of advanced neoplasia after removal of colorectal adenomas with high-grade dysplasia[J/OL]. Surgical Endoscopy, 2024, 38(7): 3783-3798. DOI:10.1007/s00464-024-10898-5. [8] BLEIJENBERG A, KLOTZ D, LØBERG M, et al. Implications of different guidelines for surveillance after serrated polyp resection in United States of America and Europe[J/OL]. Endoscopy, 2019, 51(08): 750-758. DOI:10.1055/a-0916-8598.
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk Factors for Metachronous Advanced Colorectal Lesions After Endoscopic Resection of Serrated Lesions
- ClinicalTrials.gov ID
- NCT07678788
- Acronym / sponsor ID
- 34435353
- Conditions
- Sessile Serrated Lesion, Serrated Polyp
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 750 participants (estimated)
- Lead sponsor
- Changhai HospitalUniversity, hospital or other
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 1 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to explore the risk factors associated with the development of ACN and same-site ACN in patients with SP, thereby informing the optimization of clinical surveillance strategies
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with serrated polyps at index colonoscopy and ACN at surveillance | – | – |
| Patients with serrated polyps at index colonoscopy and no ACN at surveillance | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients who underwent at least two surveillance colonoscopies at the Digestive Endoscopy Center of Shanghai Changhai Hospital between 2000 and 2025 were enrolled as study participants
Key inclusion criteria (1 listed)
- Adult patients aged > 18 years;At least one SP detected during the index colonoscopy and pathologically confirmed as TSA or SSL (according to the 2019 WHO classification criteria);Underwent complete polypectomy during the index colonoscopy;Received regular follow-up at Changhai Hospital, with an interval of ≥ 6 months between the index and follow-up colonoscopies;Complete clinical and pathological data.
Key exclusion criteria (1 listed)
- Incomplete colonoscopy or failed cecal intubation;Inadequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) score < 6 or a score < 2 in any bowel segment;Withdrawal time < 6 minutes;Diagnosis of hereditary cancer syndromes, such as familial adenomatous polyposis (FAP) or Lynch syndrome;Concurrent inflammatory bowel disease (IBD) or indeterminate colitis;History of colorectal cancer or other malignancies;Incomplete clinical or pathological records.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The occurrence of metachronous ACN
Time frame: At least 6 months after index colonoscopy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
- Background[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J/OL]. CA: A Cancer Journal for Clinicians, 2020, 70(1): 7-30. DOI:10.3322/caac.21590. [2] NAGTEGAAL I D, ODZE R D, KLIMSTRA D, et al. The 2019 WHO classification of tumours of the digestive system[J/OL]. Histopathology, 2020, 76(2): 182-188. DOI:10.1111/his.13975. [3] LI D, LIU L, FEVRIER H B, et al. Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps[J/OL]. Gastroenterology, 2020, 159(2): 502-511.e2. DOI:10.1053/j.gastro.2020.04.004. [4] ERICHSEN R, BARON J A, HAMILTON-DUTOIT S J, et al. Increased Risk of Colorectal Cancer Development Among Patients With Serrated Polyps[J/OL]. Gastroenterology, 2016, 150(4): 895-902.e5. DOI:10.1053/j.gastro.2015.11.046. [5] BAILE-MAXÍA S, MANGAS-SANJUÁN C, LADABAUM U, et al. Risk factors for metachronous colorectal cancer or advanced lesions after endoscopic resection of serrated polyps: a systematic review and meta-analysis[J/OL]. Gastrointestinal Endoscopy, 2024, 100(4): 605-615.e14. DOI:10.1016/j.gie.2024.05.021. [6] TRIVEDI M, GODIL S, DEMB J, et al. Baseline Characteristics and Longitudinal Outcomes of Traditional Serrated Adenomas: A Cohort Study[J/OL]. Clinical Gastroenterology and Hepatology, 2023, 21(6): 1637-1645. DOI:10.1016/j.cgh.2022.09.030. [7] HE D, WANG K, ZHANG Y, et al. Risk of advanced neoplasia after removal of colorectal adenomas with high-grade dysplasia[J/OL]. Surgical Endoscopy, 2024, 38(7): 3783-3798. DOI:10.1007/s00464-024-10898-5. [8] BLEIJENBERG A, KLOTZ D, LØBERG M, et al. Implications of different guidelines for surveillance after serrated polyp resection in United States of America and Europe[J/OL]. Endoscopy, 2019, 51(08): 750-758. DOI:10.1055/a-0916-8598.
- Individual participant dataSharing planned: No
Related trials for Sessile Serrated Lesion
Recruiting
Artificial Intelligence (AI) Assisted Real-time Adenoma Detection and Classification During Colonoscopies
Artificial Intelligence
Recruiting
Computer-Aided Water Exchange Colonoscopy With and Without Linked-Color Imaging for Detection of Clinically Significant Serrated Lesions
Sessile Colonic Polyp, Serrated Lesion
Not yet recruiting
Impact of Linked Color Imaging on Sessile Serrated Lesion Miss Rate
Colorectal Sessile Serrated Lesion
Recruiting
USAGE OF ARITIFICIAL INTELLIGENCE IN AIDING WITH COLONIC SESSILE SERRATED LESIONS DETECTION AND DIAGNOSIS (AI-SSL)
Sessile Serrated Lesion, CADe
Not yet recruiting
Impact of Acetic Acid-Indigo Carmine Chromocolonoscopy on Proximal Sessile Serrated Lesions
Sessile Serrated Lesion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Sessile Serrated Lesion and Serrated Polyp, run by Changhai Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yu Bai, M.D (+8619280762294, 19851132340@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The occurrence of metachronous ACN (time frame: At least 6 months after index colonoscopy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07678788, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.